A Comparison of Physiochemical Property Profiles of Development and Marketed Oral Drugs

Abstract

The process of drug discovery applies rigorous selection pressures. Marketed oral drugs will generally possess favorable physiochemical properties with respect to absorption, metabolism, distribution, and clearance. This paper describes a study in which the distributions of physiochemical properties of oral drugs in different phases of clinical development are compared to those already marketed. The aim is to identify the trends in physiochemical properties that favor a drug's successful passage through clinical development and on to the market. Two libraries were created, one of current development oral drugs and one of marketed oral drugs. Statistical analysis of the two showed that the mean molecular weight of orally administered drugs in development decreases on passing through each of the different clinical phases and gradually converges toward the mean molecular weight of marketed oral drugs. It is also clear that the most lipophilic compounds are being discontinued from development.

Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits

“…Extensive analyses indicate the significant influence of a compound's molecular properties on pharmacokinetics, toxicity, and efficacy, with success generally associated with low MW and good aqueous solubility, especially drugs that fall into the top class of the biopharmaceutics classification scheme. [16][17][18][19][20] However, increasing the aqueous solubility of a compound while decreasing MW and retaining in vivo biological function is a non-trivial goal often considered paradoxical, especially for CNS lead compounds. We summarize in this report the discovery of a novel lead compound, compound 5 (Table 1), that has improved molecular properties but retains in vivo efficacy.…”

Rational hopping of a peptidic scaffold into non-peptidic scaffolds: structurally novel potent proteasome inhibitors derived from a natural product, belactosin A

“…21 To clarify the impact of the scaffold hopping on the molecular properties as leads, we calculated binding efficiency index (BEI) and surface-binding efficiency index (SEI) of these compounds (Table 1): BEI and SEI indicate binding efficiency per molecular weight and polar surface area (PSA), respectively. 22 Because molecular weight and PSA are well known physicochemical properties wellrelated to membrane permeability and bioavailability, [23][24][25][26][27] 22 Fig . 3 shows the plot of BEI vs. SEI of the newly identified nonpeptide inhibitors 5-12 and the previously developed inhibitors with the peptide scaffold identical to that of 4.…”

A modular lead-oriented synthesis of diverse piperazine, 1,4-diazepane and 1,5-diazocane scaffolds

“…1 The molecular properties of clinical candidates [2][3][4][5] -particularly molecular size and lipophilicity 5 are strongly linked to the probability of successful negotiation of the development process. Optimisation almost inevitably leads to increases in both molecular weight and lipophilicity, making it essential to control the properties of lead compounds.…”